But, like Merck two weeks ago, GSK has failed to hit overall survival.
ApexOnco Front Page
Recent articles
Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
Conferences ramp up, and ASH abstracts near.
The group goes after a KRAS-related target on which Boehringer recently gave up.
Pelabresib is delayed, and Novartis writes off $800m of the €2.7bn purchase.
RMC-9805 looks more efficacious, and less toxic, than Astellas’s G12D degrader in pancreatic cancer.
AKY-1189 could be used in Padcev-relapsed patients, and in cancers beyond bladder.
The company reckons it’s got what it takes to hit the right member of the FGFR family.
